250 related articles for article (PubMed ID: 24434725)
21. [Use of oral glucose-lowering agents in patients with renal impairment].
Scheen AJ; Paquot N
Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
[TBL] [Abstract][Full Text] [Related]
22. Adverse effects and safety of SGLT-2 inhibitors.
Halimi S; Vergès B
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
[TBL] [Abstract][Full Text] [Related]
23. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
[TBL] [Abstract][Full Text] [Related]
24. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Wang Y; Zhao L; Huang Q; Peng Y
J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
[No Abstract] [Full Text] [Related]
25. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
26. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
Gilbert RE; Krum H
Lancet; 2015 May; 385(9982):2107-17. PubMed ID: 26009231
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological management of type 2 diabetes mellitus in patients with CKD.
Hamilton CA
J Ren Care; 2012 Feb; 38 Suppl 1():59-66. PubMed ID: 22348365
[TBL] [Abstract][Full Text] [Related]
28. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Bailey T
Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
[TBL] [Abstract][Full Text] [Related]
29. Which oral agent to use when metformin is no longer effective?
Bannon M
QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
[No Abstract] [Full Text] [Related]
30. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
[TBL] [Abstract][Full Text] [Related]
31. Management of drugs affecting blood glucose in diabetic patients with renal failure.
Charpentier G; Riveline JP; Varroud-Vial M
Diabetes Metab; 2000 Jul; 26 Suppl 4():73-85. PubMed ID: 10922977
[TBL] [Abstract][Full Text] [Related]
32. The effects of glucose-lowering therapies on diabetic kidney disease.
Agrawal V; Giri C; Solomon RJ
Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
[TBL] [Abstract][Full Text] [Related]
33. Glucose lowering and the kidney: are all drug classes equal?
Wong MG; Jardine M; Perkovic V
Lancet Diabetes Endocrinol; 2018 Nov; 6(11):835-837. PubMed ID: 30292590
[No Abstract] [Full Text] [Related]
34. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Frandsen CS; Dejgaard TF; Madsbad S
Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
[TBL] [Abstract][Full Text] [Related]
35. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
36. [Use of oral glucose-lowering agents in patients with renal impairment].
Scheen AJ
Rev Med Suisse; 2012 Aug; 8(351):1614-20. PubMed ID: 22988715
[TBL] [Abstract][Full Text] [Related]
37. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
Seufert J
Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Madsbad S; Krarup T; Deacon CF; Holst JJ
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
[TBL] [Abstract][Full Text] [Related]
40. Evolving therapeutic options for type 2 diabetes mellitus: an overview.
Guthrie RM
Postgrad Med; 2012 Nov; 124(6):82-9. PubMed ID: 23322141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]